Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03891953
Title Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

melanoma

colorectal cancer

Advanced Solid Tumor

nasopharynx carcinoma

triple-receptor negative breast cancer

Therapies

DKY709

DKY709 + Spartalizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.